Summary: New analog insulin preparations have recently become available in Poland, including long-acting analog glargine and rapid-acting analogs lispro and aspart. Thus, the era of biosimilar insulins has arrived in Poland, increasing patients' access to modern insulin preparations. The paper presents information on recent changes in the Polish insulin market, with special reference to the financial impact they might have on insulin costs covered by patients.